TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18280042

Group type: EXPERIMENTAL
Intervention: Scopolamine (cholinergic antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16173650

Group type: EXPERIMENTAL
Intervention: Ramelteon (16 mg)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Ramelteon (64 mg)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Ramelteon (16 or 64 mg)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 12930012

Group type: EXPERIMENTAL
Intervention: Dayquil/Nyquil (D/N group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Actifed DM plus paracetamol (ADM/P group)
Number of subjects: 120
Study: 10830792

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study: 8889742

Group type: EXPERIMENTAL
Intervention: High glycemic index (HGI) meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (Con) meal
Number of subjects: 6
Study: 1509578

Group type: EXPERIMENTAL
Intervention: Tandem ICON HCG-urine
Number of subjects: 0

Group type: COMPARATOR
Intervention: OPCO One-step Pacific Biotech
Number of subjects: 0
Study: 6378810

Group type: EXPERIMENTAL
Intervention: CHOL + P (leg CHO loading followed by 60-min arm exercise and a 24-h CHO-poor diet)
Number of subjects: 7

Group type: COMPARATOR
Intervention: CHOL (leg CHO loading only)
Number of subjects: 7
Study: 31138731

Group type: EXPERIMENTAL
Intervention: Clenil pressurized metered‐dose inhaler (pMDI; 250 μg) with spacer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Qvar Easi‐Breathe inhaler (100 μg) with spacer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clenil pMDI without spacer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Qvar Easi‐Breathe inhaler without spacer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Non-rinsed spacers
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rinsed spacers
Number of subjects: 12
Study: 29228091

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m2 days 1 and 15 Q28 (arm A)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m2 days 1, 8 and 15 Q28 (arm B)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 75 mg/m2 days 1, 8, 15 and 22 Q28 (arm C)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) evaluation
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Grade ≥2 sensory neuropathy
Number of subjects: 258
Study: 27212028

Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 1400

Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: 6-month DAPT (acute coronary syndrome)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: 12-month DAPT (acute coronary syndrome)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: 6-month DAPT (diabetes mellitus)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: 12-month DAPT (diabetes mellitus)
Number of subjects: 1400
Study: 24713125

Group type: EXPERIMENTAL
Intervention: e-learning continuing education program
Number of subjects: 200

Group type: COMPARATOR
Intervention: comparison group (control)
Number of subjects: 200
Study: 22492249

Group type: EXPERIMENTAL
Intervention: New gel medical device (Proctoial) containing hyaluronic acid, tea tree oil, and methyl-sulfonyl-methane
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 21416034

Group type: EXPERIMENTAL
Intervention: Community intervention training health workers to train community-based women groups in recognizing malaria symptoms and providing first-line treatment.
Number of subjects: 1715

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups.
Number of subjects: 1715
Study: 17040305

Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) 0-60 microg.kg(‐1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MET) 0-400 microg.kg(‐1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 0-500 microg.kg(‐1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of OND and MET
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Overall treatment with OND, MET, and DEX
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Children older than 7 years
Number of subjects: 240
Study: 12968984

Group type: COMPARATOR
Intervention: Omapatrilat 2.5 mg (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omapatrilat (multiple doses: 10, 25, 50, 75, or 125 mg daily for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omapatrilat (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omapatrilat (single and multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omapatrilat (multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omapatrilat (doses > 7.5 mg)
Number of subjects: 0
Study: 11460276

Group type: EXPERIMENTAL
Intervention: Toothbrush with 9,048 ppm fluoride as sodium fluoride
Number of subjects: 12
Study: 9760791

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Tilade-8 mg/24 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8473654

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3838321

Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride with iron (300 mg ferrous sulfate)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride with iron (300 mg ferrous sulfate)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride with milk
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride with milk
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride with food
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride with food
Number of subjects: 16
Study: 30457915

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) over the left lateral frontopolar cortex (FPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS) over a posterior control site
Number of subjects: 0

Group type: COMPARATOR
Intervention: No rTMS (baseline)
Number of subjects: 0
Study: 27599667

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: amlodipine 10 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 90
Study: 25824259

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin (0.5%) administered as one drop four times at 15-minute intervals starting 75 minutes before surgery.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oral moxifloxacin (400 mg) administered as a single tablet 12 hours before surgery.
Number of subjects: 42
Study: 24024773

Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate 25,000 IU/d)
Number of subjects: 84
Study: 21346614

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19296254

Group type: EXPERIMENTAL
Intervention: Polyglycoside of Tripterygium wilfordii (GTW)
Number of subjects: 39

Group type: COMPARATOR
Intervention: SASP (sulfasalazine)
Number of subjects: 39
Study: 17306507

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Brief Nutritional Education (Control)
Number of subjects: 61
Study: 15040502

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen breathing (FIO2 = 1.0, PIO2 = 460 mm Hg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ambient-air breathing (PIO2 = 86 mm Hg)
Number of subjects: 15
Study: 12126263

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.6 mg o.d.
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg o.d.
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 9651560

Group type: EXPERIMENTAL
Intervention: 16 g cholestyramine
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: 8 g cholestyramine and 20 mg pravastatin
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: 20 mg pravastatin
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: pravastatin and cholestyramine
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: cholestyramine
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: pravastatin
Number of subjects: 2036
Study: 9638202

Group type: EXPERIMENTAL
Intervention: ACTH, beta-endorphin, and cortisol secretion profiles measured on the second day after trauma
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ACTH and beta-endorphin secretion profiles
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cortisol secretion profile
Number of subjects: 12
Study: 2693326

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oophorectomy (in premenopausal patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide or progestins (in postmenopausal patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined endocrine therapy (Tamoxifen with prednisolone or androgens)
Number of subjects: 0
Study: 342319

Group type: EXPERIMENTAL
Intervention: 7 log EID50/dose
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 6 log EID50/dose
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 7 log EID50/dose (twice vaccinated)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 6 log EID50/dose (twice vaccinated)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 31043770

Group type: EXPERIMENTAL
Intervention: 0.5 µg/mL dexmedetomidine with 0.1% ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.5 µg/mL sufentanil with 0.1% ropivacaine
Number of subjects: 80
Study: 28624698

Group type: EXPERIMENTAL
Intervention: 7-min analogue mindfulness intervention (present moment attention and awareness training; PMAA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Coping-as-usual control condition
Number of subjects: 104
Study: 25446221

Group type: EXPERIMENTAL
Intervention: Low GI breakfast with exercise
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low GI breakfast with resting
Number of subjects: 42

Group type: COMPARATOR
Intervention: High GI breakfast with resting
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High GI breakfast with exercise
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low GI breakfast (regardless of exercise)
Number of subjects: 42
Study: 24169411

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (increasing community and liquor licensees' awareness, police activity, and feedback)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control communities (no intervention)
Number of subjects: 20
Study: 21697824

Group type: EXPERIMENTAL
Intervention: D2 receptor blockade (sulpiride (SULP) 400 mg)
Number of subjects: 12
Study: 19681862

Group type: EXPERIMENTAL
Intervention: R-salbutamol cream 0.5%
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 17116177

Group type: EXPERIMENTAL
Intervention: North American Caucasians (NAC)
Number of subjects: 4360
Study: 15515991

Group type: EXPERIMENTAL
Intervention: Web-based communication system
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Control group (physicians not using the Web-based communication system)
Number of subjects: 1038
Study: 11291689

Group type: EXPERIMENTAL
Intervention: PSA-ACT detection
Number of subjects: 907
Study: 9174311

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block using 10mL of 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous saline (control)
Number of subjects: 0
Study: 8175117

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.i.d.
Number of subjects: 265
Study: 3288523

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg twice daily for under 5-year-olds, 2 mg twice daily for others)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31856493

Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse yellow laser (SMYL) and intravitreal aflibercept injection (IAI) combination therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intravitreal aflibercept injection (IAI) monotherapy
Number of subjects: 56
Study: 29847184

Group type: EXPERIMENTAL
Intervention: Empowerment program (4 sessions over 4 weeks)
Number of subjects: 18
Study: 28615214

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 453

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 453
Study: 24675241

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SPLC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Classical four-port laparoscopic cholecystectomy (CLC)
Number of subjects: 40
Study: 22975538

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 62
Study: 20171080

Group type: EXPERIMENTAL
Intervention: Intrathecal magnesium sulphate 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.1 mL of 0.9% sodium chloride (control group)
Number of subjects: 60
Study: 18074471

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (ivIgG) 0.6 g/kg body weight on day 0 and 0.3 g/kg body weight on day 1
Number of subjects: 653

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (ivIgG)
Number of subjects: 653
Study: 16214045

Group type: EXPERIMENTAL
Intervention: Oral tegafur (FT) 750 mg/m2/day for 21 days and leucovorin (LV) 15 mg/m2 every 8 h in cycles repeated every 28 days
Number of subjects: 237

Group type: COMPARATOR
Intervention: Intravenous leucovorin (LV) 20 mg/m2 followed by 5-fluorouracil (5-FU) 425 mg/m2 daily for 5 days every 4 weeks for 2 cycles, and later every 5 weeks
Number of subjects: 237
Study: 12085976

Group type: EXPERIMENTAL
Intervention: Aprotinin (280 mg in pump prime)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 9972958

Group type: EXPERIMENTAL
Intervention: Insulin induced hypoglycemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone (TRH) stimulation
Number of subjects: 10
Study: 7751513

Group type: EXPERIMENTAL
Intervention: Inhaled lysine acetylsalicylate and furosemide (720 mg lysine acetylsalicylate and 40 mg furosemide twice daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2283638

Group type: EXPERIMENTAL
Intervention: Miglyol supplementation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6118715

Group type: EXPERIMENTAL
Intervention: Diet and smoking cessation intervention
Number of subjects: 1232
Study: 31856869

Group type: EXPERIMENTAL
Intervention: Educational intervention based on BASNEF model
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 28341515

Group type: EXPERIMENTAL
Intervention: Decision support with the INFANT system
Number of subjects: 47062

Group type: COMPARATOR
Intervention: No decision support
Number of subjects: 47062
Study: 25872617

Group type: EXPERIMENTAL
Intervention: Untimed group (no time limit)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Timed group (15 minutes limit)
Number of subjects: 94
Study: 23042808

Group type: EXPERIMENTAL
Intervention: CBD 600 mg
Number of subjects: 48
Study: 21336230

Group type: EXPERIMENTAL
Intervention: Message about benefits of male HPV vaccination
Number of subjects: 1178
Study: 19739937

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir plus abacavir/lamivudine (arm A)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine (arm B)
Number of subjects: 89
Study: 17544889

Group type: EXPERIMENTAL
Intervention: C‐VCM
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study: 16792054

Group type: EXPERIMENTAL
Intervention: IPS e.max Press PCR
Number of subjects: 25

Group type: COMPARATOR
Intervention: ProCAD PCR
Number of subjects: 25
Study: 12682418

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (healthy non-smokers)
Number of subjects: 30
Study: 10227944

Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three-dimensional laparoscopy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group A (Conventional then 3-D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group B (3-D then Conventional)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both inexperienced and experienced candidates
Number of subjects: 30
Study: 8561064

Group type: EXPERIMENTAL
Intervention: Diet + exercise (n = 16)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Diet only (n = 13)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Diet only (n = 12)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All groups (Diet + exercise and Diet only)
Number of subjects: 41
Study: 1899433

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy
Number of subjects: 799

Group type: COMPARATOR
Intervention: Minimal coronary lesion
Number of subjects: 799

Group type: COMPARATOR
Intervention: Significant residual stenosis
Number of subjects: 799
Study: 6871066

Group type: EXPERIMENTAL
Intervention: Fenoctimine 50 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fenoctimine 150 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fenoctimine 250 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31540617

Group type: EXPERIMENTAL
Intervention: Integrated Stepped Alcohol Treatment (ISAT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 95
Study: 29260703

Group type: EXPERIMENTAL
Intervention: Intake of five beers
Number of subjects: 0
Study: 26439559

Group type: EXPERIMENTAL
Intervention: FF+ (infant formula with scGOS/lcFOS and 30% fermented formula)
Number of subjects: 200

Group type: COMPARATOR
Intervention: IF- (infant formula without fermented formula and scGOS/lcFOS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Breastfed infants (reference group)
Number of subjects: 200
Study: 23257991

Group type: EXPERIMENTAL
Intervention: 10 ml kg(‐1) h(‐1) lactated Ringer's solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: 30 ml kg(‐1) h(‐1) lactated Ringer's solution
Number of subjects: 100
Study: 21745239

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 41
Study: 19929111

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16311773

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel tonsillectomy (HST)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Conventional steel tonsillectomy (CST)
Number of subjects: 280
Study: 15324520

Group type: EXPERIMENTAL
Intervention: CIP/DEX (ciprofloxacin 0.3%/dexamethasone 0.1%) otic suspension, 3-4 drops twice daily for 7 days
Number of subjects: 468

Group type: COMPARATOR
Intervention: N/P/H (neomycin 0.35%/polymyxin B 10,000 IU/mL/hydrocortisone 1.0%) otic suspension, 3-4 drops three times daily for 7 days
Number of subjects: 468
Study: 10908255

Group type: EXPERIMENTAL
Intervention: BQ‐123 (a selective ET(A) receptor antagonist; 100 nmol/min) in 0.9% saline, infused into the left coronary artery at a rate of 1 ml/min for 60 minutes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 14
Study: 9302398

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration (12.5 or 18 micrograms/kg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (75-90% maximum strength, 5-10 repetitions/set, 4 sets/day, 4 days/week)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Resistance exercise training plus GH
Number of subjects: 18
Study: 8094768

Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (alteplase, rt-PA) 100 mg over 2 h followed by intravenous heparin
Number of subjects: 46

Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (alteplase, rt-PA)
Number of subjects: 46
Study: 3950826

Group type: EXPERIMENTAL
Intervention: Similac With Iron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Similac With Whey + Iron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30940404

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20,000 IU of cholecalciferol once weekly for 24 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (2:1 ratio)
Number of subjects: 150
Study: 29797911

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with ibuprofen, methotrexate, and folic acid
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group treatment with ibuprofen, methotrexate, and folic acid
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medicine
Number of subjects: 56
Study: 27533265

Group type: EXPERIMENTAL
Intervention: Supervised physical therapy for upper limbs
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no supervised physical therapy)
Number of subjects: 35
Study: 25639496

Group type: EXPERIMENTAL
Intervention: Aquatic fitness plus relaxation program (3 sessions per week for 2 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no supervised exercise program)
Number of subjects: 30
Study: 23338230

Group type: EXPERIMENTAL
Intervention: Pain education plus telemonitoring
Number of subjects: 108

Group type: COMPARATOR
Intervention: Pain education alone (control arm)
Number of subjects: 108
Study: 21304082

Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 891

Group type: COMPARATOR
Intervention: Sentinel lymph node dissection (SLND) alone
Number of subjects: 891